Broadfin Capital, LLC 13F Holdings · last filed Q4 2019
Broadfin Capital, LLC reported 35 securities worth $746.81M in its SEC 13F filing for Q4 2019 (period ended 2019-12-31). Top holdings: SPY (18.96%), IWM (17.75%), BHVN1 (7.36%). Among its top 25 positions this quarter: 6 new, 8 added, 9 trimmed.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | SPY | SPDR S&P 500 ETF TR | $141.6M | 18.96% | 440,000 | Hold |
| 2 | IWM | ISHARES TR | $132.5M | 17.75% | 800,000 | New |
| 3 | BHVN1 | BIOHAVEN PHARMACTL HLDG CO L | $54.9M | 7.36% | 1.0M | Trimmed |
| 4 | XBI | SPDR SERIES TRUST | $33.3M | 4.46% | 350,000 | Trimmed |
| 5 | BDSI | BIODELIVERY SCIENCES INTL IN | $27.2M | 3.64% | 4.3M | Hold |
| 6 | ALKS | ALKERMES PLC | $25.2M | 3.37% | 1.2M | Added |
| 7 | VRAYQ | VIEWRAY INC | $23.5M | 3.15% | 5.6M | Added |
| 8 | AMRN | AMARIN CORP PLC | $22.5M | 3.01% | 1.0M | Trimmed |
| 9 | QTNT | QUOTIENT LTD | $19.0M | 2.54% | 2.0M | Added |
| 10 | EIGR | EIGER BIOPHARMACEUTICALS INC | $18.4M | 2.47% | 1.2M | Trimmed |
| 11 | STAA | STAAR SURGICAL CO | $16.3M | 2.18% | 462,118 | New |
| 12 | XENT | INTERSECT ENT INC | $15.7M | 2.10% | 631,023 | Trimmed |
| 13 | PGNX | PROGENICS PHARMACEUTICALS IN | $15.6M | 2.09% | 3.1M | Added |
| 14 | NSTG | NANOSTRING TECHNOLOGIES INC | $15.5M | 2.07% | 555,600 | Added |
| 15 | IOVA | IOVANCE BIOTHERAPEUTICS INC | $14.8M | 1.98% | 533,301 | Trimmed |
| 16 | DERM2 | DERMIRA INC | $13.6M | 1.82% | 896,334 | Added |
| 17 | SCTL | RECRO PHARMA INC | $13.2M | 1.77% | 721,073 | Trimmed |
| 18 | LNTH | LANTHEUS HLDGS INC | $12.7M | 1.70% | 617,953 | New |
| 19 | VAPO | VAPOTHERM INC | $12.2M | 1.63% | 1.0M | New |
| 20 | SIENQ | SIENTRA INC | $11.5M | 1.54% | 1.3M | Trimmed |
| 21 | VCEL | VERICEL CORP | $10.8M | 1.44% | 620,199 | Added |
| 22 | LJPC | LA JOLLA PHARMACEUTICAL CO | $10.6M | 1.41% | 2.7M | Added |
| 23 | ALXN | ALEXION PHARMACEUTICALS INC | $9.0M | 1.20% | 83,100 | New |
| 24 | SLGL | SOL GEL TECHNOLOGIES | $8.9M | 1.20% | 521,819 | Trimmed |
| 25 | RLMD | RELMADA THERAPEUTICS INC | $8.6M | 1.15% | 220,724 | New |
Source: SEC Form 13F filings · as of 2019-12-31
Every position in this 13F-HR, with its change from the prior quarter.
13F holdings, latest quarter
SourceSEC EDGAR13F-HR